Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2016, vol. 22, issue 4
Subject Area: Medicine
Pages: 1403-1406
DOI: 10.5272/jimab.2016224.1403
Published online: 21 December 2016

J of IMAB 2016 Oct-Dec;22(4):1403-1406
Lidija Kareva Corresponding Autor,
Clinic for children’s disease, Department of immunology, Faculty of Medicine - Skopje, Macedonia.

Intravenous immunoglobulin (IVIG) is a blood product prepared from the serum of of a thousand or more blood donors. The IVIG that is available contains complete immunoglobulin G( IgG )molecules which has intact Fc-dependent effector functions. The IgG subclasses match those in normal human serum. It is the main treatment for patients with antibody deficiencies. High dose IVIG (hdIVIG), is used as an immunomodulatory agent in an increasing number of immune and inflammatory disorders. The clinical specialities using the largest amounts of IVIG are neurology, haematology, immunology, nephrology, rheumatology and dermatology. In this paper, we review recent developments in the understanding of mechanisms of action of IVIG and the major clinical areas of use.

Key words: immunology, intravenous immunoglobulin,

- Download FULL TEXT /PDF 479 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Kareva L. Intravenous immunoglobulin therapy in medical praxis. J of IMAB. 2016 Oct-Dec;22(4):1403-1406. DOI: 10.5272/jimab.2016224.1403.

Correspondence to: Dr. Lidija Kareva, Slavej Planina 8, 1000 Skopje, Macedonia; E-mail:

1. Lamari F, Anastassiou ED, Tsegenidis T, Dimitracopoulos G, Karamanos NK. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal. 1999 Sep;20(6):913-20. [PubMed]
2. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by sta-phylococcal toxin superantigens. J Clin Invest. 1993 Feb;91:602–7
3. Barahona Afonso AF, João CM. The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules. 2016 Mar 9;6(1):15. [CrossRef].
4. US Food and Drug Administration. Drugs. 2013 [Internet]
5. Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012 Dec;40(6):601-11. [PubMed] [CrossRef].
6. Kareva L, Mironska K, Stavric K. Joint disease in children with X-linked agamaglobulinemia. J of IMAB. 2013 Jul-Dec;19(3):457-460. [CrossRef]
7. Toth B, Volokha A, Pac M, Bernatovska E, Kareva L, Marodi L, et al. Genetic and demografic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol. 2009 Jun;46(10):2140-6. [CrossRef]
8. Stavri K, Peova S, Mironska K, Kareva L. Asociation of gastroesofageal reflux and IgG2 deficiency. Children’s pulmology, Belgrade. 2000; 8(1):69-72
9. Cotugno N, Manno EC, Stoppa F, Sinibaldi S, Saffirio C, D'Argenio P, et al. Severe parainfluenza pneumonia in a case of transient hypogammalobulinemia of infancy. BMJ Case Rep. 2013 Jun 26;2013. [PubMed] [CrossRef]
10. Günther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol. 2013 Jul;57(7):527-35. [PubMed] [CrossRef]
11. Jaffe EF, M. Lejtenyi MC, Noya FJD, Mazer BD. Secondary Hypogammaglobulinemia. Immunol Allergy Clin North Am. 2001 Feb;21(1):141-163.
12. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013 Jul 2;(7):CD000361. [PubMed] [CrossRef]
13. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004; (1):CD001239. [PubMed] [CrossRef]
14. Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090. [PubMed] [CrossRef]
15. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007 Dec;35(12):2677-85. [PubMed]
16. Zhou Z, Qiao Z, Li H, Luo N, Zhang X, Xue F, et al. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases. Autoimmunity. 2016; 49(1):50-7. [PubMed] [CrossRef]
 17. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993 Dec;44(4):237-42. [PubMed]
18. Sakthiswary R, D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2014 Oct;93(16):e86. [PubMed] [CrossRef]
19. Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016 Jan;55(1):115-9. [PubMed]
20. Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015 Aug;14(8):651-8. [PubMed] [CrossRef]
21. Niggemann B, Leupold W, Schuster A, Schuster R, v Berg A, Grübl A, et al. Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma. Clin Exp Allergy. 1998 Feb;28(2):205-10. [PubMed]
22. Nikolov N, Reisinger J, Schwarz HP. 10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders. Immunotherapy. 2016 Jul;8(8):923-40. [PubMed] [CrossRef].
23. Lünemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016 Jan;13(1):34-46. [PubMed] [CrossRef]
24. Perez Nellar J, Dominguez AM, Llorens-Figueroa JA, Ferra-Betancourt A, Pardo A, Quiala M, et al. [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia]. [in Spanish] Rev Neurol. 2001 Sep 1-15;33(5):413-6. [PubMed]
25. Zare-Shahabadi A, Rashidian A, Sahraian MA, Rezaei N. Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review. Expert Rev Clin Immunol. 2015;11(12):1291-5. [PubMed] [CrossRef]
26. Bello-Espinosa LE, Rajapakse T, Rho JM, Buchhalter J. Efficacy of intravenous immunoglobulin in a cohort of children with drug-resistant epilepsy. Pediatr Neurol. 2015 May;52(5):509-16. [PubMed] [CrossRef]
27. Cowan J, Cameron DW, Knoll G, Tay J. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. BMJ Open. 2015 Aug 21;5(8):e008316. [PubMed] [CrossRef]
28. Taber T, Mujtaba MA, Goggins W, Higgins N, Sharfuddin A, Yaqub MS, et al. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. Clin Transplant. 2013 Jul-Aug;27(4):E375-82. [CrossRef
29. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr. 2004 Apr;144(4):496-9. [PubMed]
30. Ririe MR, Blaylock RC, Morris SE, Jung JY. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis. J Am Acad Dermatol. 2013 Aug;69(2):221-5. [PubMed] [CrossRef]
31. Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016 Apr;74(4):700-8.e3. [PubMed] [CrossRef]
32.  Whitehouse AJ. Complementary and alternative medicine for autism spectrum disorders: rationale, safety and efficacy. J Paediatr Child Health. 2013 Sep;49(9):E438-42:quiz E442. [PubMed] [CrossRef].

Received: 13 October 2016
Published online: 21 December 2016

back to Online Journal